Edward Bastyr, MD, Endocrinology, Indianapolis, IN, Eskenazi Health

EdwardJBastyrMD

Endocrinology Indianapolis, IN

Diabetes, Lipid Metabolism

Consultant, Diabetes Drug Development, Associate Professor (voluntary), Indiana University School of Medicine

Dr. Bastyr is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bastyr's full profile

Already have an account?

Summary

  • Dr. Edward Bastyr is an endocrinologist in Indianapolis, IN and is affiliated with Eskenazi Health. He received his medical degree from Universidad de Navarra Faculty of Medicine and has been in practice 34 years. He also speaks multiple languages, including Spanish. He specializes in diabetes and lipid metabolism and is experienced clinical researcher in diabetes mellitus and obesity and obesity-related disorders.

Education & Training

  • University of Michigan Hospitals and Health Centers
    University of Michigan Hospitals and Health CentersFellowship, Endocrinology, Diabetes and Metabolism, 1985 - 1988
  • University of Pittsburgh Medical Center-Mercy Hospital
    University of Pittsburgh Medical Center-Mercy HospitalResidency, Internal Medicine, 1983 - 1985
  • University of Pittsburgh Medical Center-Mercy Hospital
    University of Pittsburgh Medical Center-Mercy HospitalInternship, Internal Medicine, 1982 - 1983
  • Universidad de Navarra Faculty of Medicine
    Universidad de Navarra Faculty of MedicineClass of 1982
  • Wagner CollegeMS, Microbiology, 1977 - 1978
  • University of Chicago
    University of ChicagoMS, Biochemistry, 1976 - 1977
  • Columbia College, Columbia University
    Columbia College, Columbia UniversityAB, Biochemistry, 1972 - 1976

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1995 - 2021
  • TX State Medical License
    TX State Medical License 1989 - 1996
  • PA State Medical License
    PA State Medical License 1983 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • President's Recognition Award For Outstanding Scientific Achievement (1% Award) Lilly Research Laboratories, 2002, 2009, 2014
  • Lincoln Fund Fellow Rockefeller University, 1975
  • Honorarium University of Pittsburgh, 1973

Publications & Presentations

PubMed

Journal Articles

  • A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 ...  
    Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Qu Y, Antalis CJ, Hartman ML, Rosilio M, Jacober SJ, Bastyr EJ III and on behalf of the IMAGINE 3 Trial Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
  • Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 dia...  
    Blevins T, Pieber TR, Colon Vega G, Zhang S, Bastyr EJ III, Chang AM and on behalf of the IMAGINE 4 Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
  • A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAG...  
    Garg S, Dreyer M, Jinnouchi H, Mou J, Qu Y, Hartman ML, Rosilio M, Jacober SJ, Bastyr EJ III and on behalf of the IMAGINE 1 Trial Investigators, Diabetes, Obesity and Metabolism, 1/1/2016
  • Join now to see all

Abstracts/Posters

  • Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in an Open-label, Randomized Study in T1D Patients (pts): IMAGINE 1
    Garg SK, Jinnouchi H, Dreyer M, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 1 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Superior HbA1c Reduction with Basal Insulin Peglispro (BIL) vs Insulin Glargine (GL) and Preprandial Insulin Lispro in a Double-blind Study in Patients (pts) with Type...
    Blevins T, Pieber TR, Vega GC, Zhang S, Bastyr EJ III, Chang AM, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Superior Reduction of HbA1c in a Double-blind, Randomized Study of Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in Patients (pts) with T1D: IMAGINE 3
    Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Hartman ML, Rosilio M, Bastyr EJ III for the IMAGINE 3 Study Group, American Diabetes Association National Meeting; Diabetes, Boston, MA, 1/1/2015
  • Join now to see all

Lectures

  • Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical Trials 
    Indianapolis, IN - 6/14/2014
  • LY2605541, A Novel Long-Acting Basal Insulin Analog 
    Colegio de Medicos de España, Madrid, Spain - 1/1/2012
  • Postprandial Blood Glucose is a Better Predictor of Overall Metabolic Control in Diabetes Mellitus 
    Norfolk, VA - 1/1/2000
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish

Hospital Affiliations